Pfizer Stock News

Having an effective anti-viral in its arsenal could help China mitigate the lower efficacy of its homegrown vaccines if the virus was allowed to circulate …

New research on Pfizer''s COVID vaccine shows how much better three doses are compared to two. Kaiser Permanente did the study that was published in Lancet Regional Health medical journals.

COVID-19 vaccine boosters from Pfizer Inc (NYSE: PFE ) / BioNTech SE (NASDAQ: BNTX ) and Moderna Inc (NASDAQ: MRNA ) become less effective after four months but still provide significant protection against hospitalization, a CDC study found. While vaccine efficacy was still strong two months after a booster shot, it declined significantly after four months. Efficacy against COVID-19associated emergency department visits and Full story available on Benzinga.com

ABC News published this video item, entitled "FDA delays review of Pfizer vaccine for kids under 5" - below is their description.

The efficacy of third doses of the Pfizer and Moderna mRNA vaccines wanes substantially by the fourth month after administration, a new study by the US Centers of Disease Control and Prevention (CDC)…

Las Vegas Sands gained the most of any consumer stock in the S&P 500 Index after the emergency approval of the Pfizer antiviral pill. Read more.

A delay for Pfizer and BioNTech appears to be weighing on all vaccine stocks.

"One case in one direction or another can tip the perception of the vaccine''s overall effectiveness," said the Pfizer board member and former FDA chief.

BioNTech SE (NASDAQ: BNTX ) is trading lower Monday morning after the U.S. Food and Drug Administration (FDA) requested additional data before approving its COVID-19 vaccine for children aged six months to four years old. Pfizer Inc (NYSE: PFE ) and BioNTech extended their rolling submission to the FDA seeking to amend the Emergency Use Authorization of the Pfizer-BioNTech COVID-19 vaccine to include the aforementioned age group. In December, the two … Full story available on Benzinga.com

CNBC Television published this video item, entitled "Scott Gottlieb breaks down Pfizer''s delayed Covid vaccine for young children" - below is their description.

Pfizer (PFE) and Biohaven Pharmaceutical (BHVN) announced that rimegepant known as NURTEC ODT in the U.S

Dr. Scott Gottlieb, former FDA commissioner and CNBC contributor, joins CNBC''s ''Squawk Box'' to explain why Pfizer and the FDA delayed the company''s application for its Covid-19 vaccine in young children.

Biohaven Pharmaceutical Holding Company Ltd (NYSE: BHVN ) and Pfizer Inc (NYSE: PFE ) reported topline results from an Asia-Pacific, Phase 3 trial of rimegepant in adults for the acute treatment of migraine. The study met its co-primary endpoints of freedom from pain and freedom from most bothersome migraine-associated symptom, including either nausea, phonophobia, or photophobia at 2-hours following a single oral dose … Full story available on Benzinga.com

This article was originally published on TipRanks.com. The post Pfizer Bags Conditional Approval for COVID-19 Drug Paxlovid in China — Report appeared first on Smarter Analyst .